×
The central target reviewed here is $13 , the arithmetic mean of roughly a dozen verified analyst price targets collected from individual firms. That target sits about 34% above the latest verified close of $9.73 (November 3, 2026), so the implied move is substantial rather than incremental.
Dentsply Sirona (XRAY) shares climbed roughly 23% over the past 30 days, rebounding from about $8.56 in early October to near $10.54. The recovery followed a series of commercial, reimbursement, and balance-sheet developments, including expanded North American distribution partnerships and debt covenant relief.
Third-quarter 2026 revenue reached $154.5 million, up 15% year over year and ahead of the roughly $151 million consensus estimate. AtriCure returned to profitability, posting net income of $4.1 million versus a net loss of $0.3 million in the prior-year quarter.
Stevanato Group is scheduled to report results for the third quarter of fiscal 2026 (the three months ended September 30, 2026), with results widely expected around the first half of November 2026. Investors are watching whether the company sustains its high-value solutions momentum, after those products grew 16% in the second quarter and reached 45% of total revenue.
Stevanato Group (STVN) shares fell roughly 28% over the trailing 30 days, with the bulk of the decline occurring in a single trading session after its third-quarter 2026 report. Third-quarter revenue rose 8% to €326.1 million and adjusted diluted EPS of €0.16 matched consensus, but forward commentary on GLP-1 demand pressured the stock.
Stevanato Group (STVN) fell sharply in early regular trading, dropping from a $19.74 prior close to roughly $14.01, a -29.03% decline, after reporting third-quarter results before the open. The drop was driven by Q3 results that were in line with estimates (adjusted EPS €0.16) but paired with guidance warning of lower GLP-1-related volumes and revenue in 2027, as management now expects only "low single digit" growth next year.
ICLR (ICON plc) is a global contract research organization (CRO) with a large, visible backlog and consistent profitability, while RGEN (Repligen Corporation) is a life-sciences tools maker riding a bioprocessing recovery with faster organic growth. Both names carry "Buy" analyst consensus, but ICLR offers steadier earnings visibility, whereas RGEN carries more acquisition and margin-related volatility.
Retail expansion is the central growth catalyst: management is in negotiations with major U.S. big-box retailers, positioning for a potential brick-and-mortar rollout in 2026 across optical and hardware departments. Lucyd Armor smart safety glasses are the engine: the fastest-growing product line now accounts for roughly half of smart-glass units sold, supported by U.S., Canadian, and European Union safety certifications.
The $3.00 target used in this article comes from the only current published price objective in the public domain — a single analyst target from Maxim Group — not from a multi-analyst consensus. With shares near $0.83, reaching $3.00 would require roughly 260% upside, a very large move.
LUCY shares traded near $0.83 in late October 2026, down roughly 8.7% from about $0.91 at the end of September — a pullback that keeps the absolute 30-day move below 10%. The stock remains well below its 52-week high of $2.02 and sits within a low-priced, micro-cap trading range with a market capitalization near $7 million.
Net sales rose 11% year over year to $20.6 million, ahead of the roughly $20.40 million consensus estimate. Diluted earnings per share (EPS) came in at $0.92, well above the estimated $0.66, though below the prior-year quarter's $1.40.
Merit Medical Systems (MMSI) reported third-quarter 2026 revenue of $416.2 million, up 8.4% year over year, with organic constant currency growth of 9%. Non-GAAP earnings per share (EPS) came in at $1.12, ahead of the roughly $1.04 per share consensus estimate, while GAAP EPS was $0.70.
AptarGroup reported third quarter 2026 adjusted earnings per share (EPS) of $1.52 , beating the analyst consensus estimate of $1.47 by $0.05. Revenue came in at approximately $1.02 billion , topping consensus expectations of roughly $981 million and rising about 6% year over year.
Baxter International reported Q3 2026 revenue of $2.98 billion, up 5% year over year and above the roughly $2.91 billion Wall Street consensus estimate. Adjusted earnings per share (EPS) came in at $0.58, topping the $0.52 consensus and beating expectations by about 12%.
Third-quarter revenue rose 8.7% year over year to $874.5 million, with organic (currency-adjusted) growth of 11.9%. Adjusted earnings per share (EPS) climbed 36% to $2.66, roughly 21% above Wall Street's consensus estimate of $2.20.
ResMed reported revenue of approximately $1.415 billion for the first quarter of fiscal 2027, up 6% year over year and 7% on a core constant currency basis, topping consensus estimates near $1.39 billion. GAAP (Generally Accepted Accounting Principles) diluted EPS (earnings per share) rose 23% to $2.92, while non-GAAP diluted EPS increased 14% to $2.91, both above analyst expectations.
Align Technology reported Q3 2026 revenue of $1.015 billion , up 1.9% year over year and slightly above the roughly $1.01 billion consensus estimate. Adjusted (non-GAAP) diluted earnings per share came in at $2.80 , beating analyst expectations of approximately $2.78; GAAP diluted EPS was $1.90.
Avantor (AVTR) reported third-quarter 2026 net sales of $1.70 billion, up 4.6% year over year, with organic growth of 5.2%. Adjusted earnings per share (EPS) came in at $0.22, ahead of the $0.21 Wall Street consensus, while GAAP (Generally Accepted Accounting Principles) diluted EPS was $0.30.
Avantor (AVTR) traded near $16.27 in late October 2026, up roughly 6% from its level 30 days earlier, reflecting a steady uptrend rather than a sharp, volatile spike. Third-quarter 2026 results marked a return to organic revenue growth of 5.2%, with net sales of $1.70 billion rising 4.6% year over year and exceeding consensus estimates.
Repligen posted record third-quarter revenue of $209.3 million, up 10.9% year over year and slightly ahead of the roughly $207 million consensus estimate. Adjusted earnings per share (EPS) of $0.53 beat analyst expectations of $0.46, while organic revenue growth reached 12.5%.